Neurological development of children born to liver transplant recipients
J Schreiber-Zamora1, B Kociszewska-Najman1, B Borek-Dzięcioł1
1Division of Neonatology, 1st Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland.
Insights
Children born to mothers who received liver transplants show normal neurological development, similar to those in a control group. This indicates immunosuppressive treatment during pregnancy does not negatively impact child neurodevelopment.
Area of Science:
- Pediatric Neurology
- Transplant Medicine
- Obstetrics
Background:
- Immunosuppressive therapy in pregnant liver transplant recipients (LTRs) raises concerns about potential adverse effects on fetal development.
- Assessing the long-term neurological outcomes in children born to LTRs is crucial for understanding the safety of such treatments during pregnancy.
Purpose of the Study:
- To conduct a neurological assessment of infants and children born to liver transplant recipients.
- To compare the neurological development of children born to LTRs with a control group of children born to non-recipients.
Main Methods:
- A cohort of 88 children was studied: 44 born to LTR mothers and 44 to non-recipients, matched for gestational age.
- Neurological examinations were performed on children aged 7 weeks to 10 years by a pediatric neurologist.
- Statistical analysis utilized the Fisher's exact test to compare developmental outcomes.
Main Results:
- Normal neurological development was observed in 79.54% of children in the LTR group and 88.63% in the control group (P = .3827).
- Slight neurological disorders were present in 13.63% of the LTR group and 11.36% of the control group.
- Moderate disorders were found in 6.81% of the LTR group; no severe disorders were noted in either group.
Conclusions:
- Neurological development in children born to mothers who underwent liver transplantation is comparable to that of children from mothers without organ transplants.
- Chronic immunosuppressive treatment during fetal life does not appear to adversely affect the neurological development of offspring.
Introduction:
Immunosuppressive treatment used in pregnant liver recipients may have a negative impact on fetal development and successively a child.
Aim:
The aim of the study was to make a neurological assessment of infants and children born to liver transplant recipients (LTRs) born between December 4, 2001, and February 11, 2013, in the 1(st) Department of Obstetrics and Gynecology, Medical University of Warsaw.
Methods And Materials:
The study involved 88 children, of whom 44 children were born to LTR mothers, and 44 children born to women who were not organ recipients and delivered at a similar gestational age. The gestational age of neonates ranged from 33 to 41 weeks, and the birth weight ranged from 1420 g to 4100 g. The neurological examination was performed in children from 7 weeks to 10 years of age. The neurological development was assessed by a specialist in pediatric neurology. The results of the examination were divided according to the following criteria: 1) normal development, 2) slight disorders, 3) moderate disorders, and 4) severe disorders. The Fisher's exact test was used for statistical analysis.
Results:
Normal development was found in 35 of 44 (79.54%) children in the LTR group and 39 of 44 (88.63%) children in the control group (P = .3827). Slight disorders were observed in 6 of 44 (13.63%) children in LTR group and 5 of 44 (11.36%) children in the control group. Moderate disorders were found only in 3 of 44 (6.81%) children in the LTR group. No severe disorders were observed in both groups.
Conclusions:
Neurological development of children born to the liver recipients who were exposed to chronic immunosuppressive treatment in their fetal lives is the same as that of children whose mothers have not undergone organ transplantation.
Related Concept Videos
Kidney Transplant I: Introduction
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Kidney Transplant III: Nursing Management
Pharmacokinetics in Pediatric Patients: Drug Metabolism


